By Jeff Overley ( July 15, 2015, 7:46 PM EDT) -- The U.S. Food and Drug Administration on Wednesday kicked off discussions over the next round of pharmaceutical industry user fees to support brand-name product approvals, hearing repeated pleas for better communication, more money and enhanced consideration of patient prerogatives. Here are three takeaways from a public workshop....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.